Narcolepsy Global Market Report 2024

Narcolepsy drugs are medications specifically formulated to manage and alleviate the symptoms of narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness (EDS), sudden episodes of muscle weakness or paralysis (cataplexy), sleep paralysis, and hallucinations. These medications are often used in combination and customized to meet the individual needs of patients, aiming to enhance their quality of life by reducing the severity of narcolepsy symptoms.

The main types of narcolepsy drugs address narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy. Narcolepsy with Cataplexy involves sudden, temporary muscle weakness or paralysis triggered by intense emotions such as laughter, surprise, or anger. Various medications are used to treat symptoms such as excessive daytime sleepiness, cataplexy, and other related conditions. These therapeutics include sodium oxybate, central nervous system stimulants, tricyclic antidepressants, selective serotonin reuptake inhibitors, and other treatments.

The narcolepsy drugs market research report is one of a series of new reports that provides narcolepsy drugs market statistics, including narcolepsy drugs industry global market size, regional shares, competitors with a narcolepsy drugs market share, detailed narcolepsy drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the narcolepsy drugs industry. This narcolepsy drugs research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The narcolepsy drugs market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.62 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increased awareness and diagnosis of narcolepsy, improved treatment options becoming available, regulatory approvals for new therapies, rising rates of awareness and diagnosis among healthcare providers and the public, and the expansion of healthcare services aimed at managing neurological disorders.

The narcolepsy drugs market size is expected to see strong growth in the next few years. It will grow to $5.23 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to several factors including the rising prevalence of sleep disorders, advances in personalized medicine, an aging population more susceptible to sleep disorders, increasing support and assistance programs for patients, and expanding healthcare coverage. Major trends anticipated during this period include technological innovations, pharmaceutical companies adopting more patient-centric approaches, ongoing research and development in biologic therapies, the development of innovative drug formulations, and a growing preference for non-stimulant alternatives in treatment.

The narcolepsy drugs market is expected to experience growth driven by increasing demand for personalized medicine. Personalized medicine involves tailoring treatments to meet individual patient needs, leveraging advancements in omics technology, data integration, genetics, and a deeper understanding of personalized therapies and preventative measures. Narcolepsy drugs play a crucial role in personalized medicine by customizing treatment plans based on factors such as genetic profiles, symptom severity, metabolic rates, and patient preferences, aiming to maximize efficacy while minimizing side effects. For example, the Personalized Medicine Coalition reported a notable increase in approvals of customized medications in 2022, accounting for 34% of newly approved treatments, highlighting the growing preference for personalized approaches. Thus, the rising demand for personalized medicine is a key driver of growth in the narcolepsy drugs market.

Leading companies in the narcolepsy drugs market are innovating with products such as extended-release therapeutics to improve treatment outcomes and patient satisfaction. Extended-release (ER) formulations offer benefits such as improved medication adherence, stable drug levels, reduced side effects, and enhanced symptom management for narcolepsy patients. For instance, Avadel Pharmaceuticals recently introduced Lumryz, an extended-release sodium oxybate medication approved by the US FDA. Lumryz features an innovative mechanism that maintains consistent therapeutic levels overnight with a single dose, offering convenience and potentially improving patient compliance compared to traditional dosing schedules. This advancement addresses a significant need in narcolepsy treatment, aiming to simplify therapy and enhance overall quality of life for patients.

In May 2022, Axsome Therapeutics Inc., a US biopharmaceutical company, acquired Sunosi from Jazz Pharmaceuticals for $53 million. This acquisition expands Axsome's portfolio in the central nervous system (CNS) area by incorporating Sunosi, a medication designed to promote wakefulness in adults with excessive daytime sleepiness linked to narcolepsy or obstructive sleep apnea. Jazz Pharmaceuticals, based in Ireland, is a prominent player in the narcolepsy drugs market.

Major companies operating in the narcolepsy drugs market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Sun Pharmaceutical Industries Ltd., Jazz Pharmaceutical plc, Ipsen Group, Lundbeck AS, Hikma Pharmaceuticals plc, Lupin Limited, Viatris Inc., Harmony Biosciences Holdings Inc., Ligand Pharmaceuticals Incorporated, Sumitomo Dainippon Pharma Co. Ltd., Avadel Pharmaceuticals plc, Bioprojet Pharma s.a.r.l, Graymark Healthcare Inc., Flamel Technologies SA, Arena Pharmaceuticals.

North America was the largest region in the narcolepsy drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the narcolepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the narcolepsy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The narcolepsy drugs market consists of sales of orexin receptor antagonists, stimulants, and orexin-based therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.